Nuuron

Imagine Treating Alzheimer’s with Drugs Made of Software Instead of Molecules. At Nuuron, we call it Digital Drugs. Our team of scientists has unlocked the brain’s memory code, enabling us to develop software as a therapeutic tool. Nuuron's Digital Drugs are delivered through the retina, an interface into the brain, using ultra-high-frequency digital-photonic stimulation. This targeted approach activates the neural networks responsible for memory formation and recall. In healthy individuals, Nuuron's Digital Drug has shown significant improvements in memory. Now, we’re on a mission to bring this groundbreaking therapy to patients suffering from Alzheimer’s Disease. To make this a reality, Nuuron has raised €3.5 million from top investors, including visionary family offices and best-in-class business angels. We’re also excited to announce a strategic partnership with RoX Health, part of Roche's Digital Pharma division. With this funding, we’re launching animal studies in collaboration with the German Center for Neurodegenerative Diseases (DZNE) and preparing for a clinical trial with Alzheimer’s patients at Charité. At both sites, we’ve encountered world-class scientists and inspiring colleagues who share and support our vision. At Nuuron, science meets a founder’s mentality—the best of both worlds to turn a visionary technology into a reality for those who can't afford to wait. #DigitalDrugs #Neurotech #AlzheimersTreatment #Innovation #Nuuron #MemoryHack #DigitalHealth #HTGF #IBBVentures #BACB

Our Lead Scientist Julian presents our groundbreaking findings at the Salzburg Mind and Brain Annual Meeting (SAMBA) this year. Within just one year we made remarkable progress in the development of a new type of Alzheimer's therapy. The best is yet to come, stay tuned.

A year ago our journey began with a vision: to enhance the complex processes by which our brain forms memories, stores information and recalls the past.   This led to our breakthrough discovery: We can stimulate the hippocampus, the epicenter of cognitive navigation, through targeted stimulation of the retina. This concept paves the way for an entirely novel, non-invasive way to treat Alzheimer’s Disease. We create a reality, where memories aren’t lost, but can be found again.   Today, we are proud to announce our partnership with #RoX. Together, we will accelerate our pathway to develop the „Memory-Pacemaker“, a disease modifying therapy to treat Alzheimer’s Disease by enhancing core electrophysiological activities in the brain.    #Alzheimer #MemoryPacemaker #SharpWaveRipples #Neuroscience #Roche